Reassessing The Changing Outlook For Pacific Biosciences of California Inc (PACB)
Currently, there are 300.04M common shares owned by the public and among those 264.16M shares have been available to trade. The company’s stock has a 5-day price change of -10.76% and -41.65% over the past three months. PACB shares are trading -50.26% year to date (YTD), with the 12-month market performance down to -50.80% lower. […]
Pacific Biosciences of California Inc (NASDAQ: PACB): Hunting Genuine Value In Market Debris
Currently, there are 300.04M common shares owned by the public and among those 264.15M shares have been available to trade. The company’s stock has a 5-day price change of -7.59% and -44.05% over the past three months. PACB shares are trading -43.44% year to date (YTD), with the 12-month market performance down to -53.59% lower. […]
Pacific Biosciences of California Inc (NASDAQ: PACB): The Best-Of-Breed For Investing?
Currently, there are 300.04M common shares owned by the public and among those 264.11M shares have been available to trade. The company’s stock has a 5-day price change of -0.90% and -17.29% over the past three months. PACB shares are trading -39.89% year to date (YTD), with the 12-month market performance down to -34.52% lower. […]
Gains May Be On The Menu For Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 294.42M common shares owned by the public and among those 264.11M shares have been available to trade. The company’s stock has a 5-day price change of -0.90% and -23.61% over the past three months. PACB shares are trading -39.89% year to date (YTD), with the 12-month market performance down to -37.50% lower. […]
Pacific Biosciences of California Inc (PACB): A Great Stock For Handling Current Market Conditions?
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of -0.88% and -32.34% over the past three months. PACB shares are trading -38.25% year to date (YTD), with the 12-month market performance down to -16.91% lower. […]
Reassessing The Changing Outlook For Pacific Biosciences of California Inc (PACB)
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of -11.36% and -31.18% over the past three months. PACB shares are trading -36.07% year to date (YTD), with the 12-month market performance down to -19.86% lower. […]
Growing Through Challenges? – Pacific Biosciences of California Inc (PACB)
Currently, there are 267.44M common shares owned by the public and among those 253.36M shares have been available to trade. Insiders at the company have transacted a total of 19 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]
Pacific Biosciences of California Inc (NASDAQ: PACB) – Suitable For Long Term Buy?
Currently, there are 267.44M common shares owned by the public and among those 256.44M shares have been available to trade. Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]
These Numbers Could Change Investor Views For Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 267.44M common shares owned by the public and among those 256.44M shares have been available to trade. Insiders at the company have transacted a total of 21 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, […]
Pacific Biosciences of California Inc (PACB): Street Finally Waking Up
ARK Investment Management LLC recently announced the acquisition of new stake in Pacific Biosciences of California Inc (NASDAQ:PACB). The institutional investor has increased its shareholding in the Healthcare company by 15.70% to 34.5 million shares with purchase of 4.68 million shares. This fresh investment now brings its stake to 12.90% valued currently at $338.49 million. […]